Biohaven stock slides 15% amid data presentations

seekingalpha04-16

Shares of Biohaven (NYSE:BHVN) slid 15% in early afternoon trading Monday amid presentations for its various drug candidates at two industry meetings. Early Monday, Biohaven said that the inventor of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427937884?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg","is_english":true,"pubTime":"2024-04-16 01:54","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2427937884","market":"fut","top_or_hot":-1,"title":"Biohaven stock slides 15% amid data presentations","media":"seekingalpha","content":"<div>\n<p>Shares of Biohaven (NYSE:BHVN) slid 15% in early afternoon trading Monday amid presentations for its various drug candidates at two industry meetings.  Early Monday, Biohaven said that the inventor of...</p>\n\n<a href=\"https://seekingalpha.com/news/4089737-biohaven-stock-slides-amid-data-presentations\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven stock slides 15% amid data presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven stock slides 15% amid data presentations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-16 01:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4089737-biohaven-stock-slides-amid-data-presentations><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Biohaven (NYSE:BHVN) slid 15% in early afternoon trading Monday amid presentations for its various drug candidates at two industry meetings.  Early Monday, Biohaven said that the inventor of...</p>\n\n<a href=\"https://seekingalpha.com/news/4089737-biohaven-stock-slides-amid-data-presentations\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4089737-biohaven-stock-slides-amid-data-presentations","article_id":"2427937884","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427937884","pubTimestamp":1713203660,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Biohaven  slid 15% in early afternoon trading Monday amid presentations for its various drug candidates at two industry meetings.  Early Monday, Biohaven said that the inventor of its MoDE technology, Dr. David Spiegel of Yale University, presented an update on the company’s degrader technology and a summary of its progress on a Phase 1 study for its drug BHV-1300 at the ABI Conference in the UK, which runs from April 15 to 17. On Saturday, the company also said that it would be presenting 20 abstracts on various drug candidates at the American Academy of Neurology annual meeting in Denver over the weekend. The company also plans to present data from an ongoing study of its drug BHV-1300 at its annual R&D day on May 29.  More on Biohaven  Biohaven's Bounce Back: A Missed Call Turns Bullish  RBC Capital starts Biohaven at outperform, cites epilepsy drug UBS starts Biohaven at buy, cites diverse pipeline Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Bioh","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技"},"translate_title":"Biohaven股票在数据发布中下跌15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"Shares of Biohaven (NYSE:BHVN) slid 15% in early afternoon trading Monday amid presentations for its various drug candidates at two industry meetings.  Early Monday, Biohaven said that the inventor of its MoDE technology, Dr. David Spiegel of Yale University, presented an update on the company’s degrader technology and a summary of its progress on a Phase 1 study for its drug BHV-1300 at the ABI Conference in the UK, which runs from April 15 to 17. On Saturday, the company also said that it would be presenting 20 abstracts on various drug candidates at the American Academy of Neurology annual meeting in Denver over the weekend. The company also plans to present data from an ongoing study of its drug BHV-1300 at its annual R&D day on May 29.  More on Biohaven  Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade) RBC Capital starts Biohaven at outperform, cites epilepsy drug UBS starts Biohaven at buy, cites diverse pipeline Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohaven","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427937884"}